First Time Loading...

Cyclo Therapeutics Inc
NASDAQ:CYTH

Watchlist Manager
Cyclo Therapeutics Inc Logo
Cyclo Therapeutics Inc
NASDAQ:CYTH
Watchlist
Price: 1.41 USD 0.71% Market Closed
Updated: May 15, 2024

Intrinsic Value

CYTH doesn't have a meaningful market cap.
CYTH's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. [ Read More ]

The intrinsic value of one CYTH stock under the Base Case scenario is 0.56 USD. Compared to the current market price of 1.41 USD, Cyclo Therapeutics Inc is Overvalued by 60%.

Key Points:
CYTH Intrinsic Value
Base Case
0.56 USD
Overvaluation 60%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cyclo Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CYTH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Cyclo Therapeutics Inc

Provide an overview of the primary business activities
of Cyclo Therapeutics Inc.

What unique competitive advantages
does Cyclo Therapeutics Inc hold over its rivals?

What risks and challenges
does Cyclo Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Cyclo Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cyclo Therapeutics Inc.

Provide P/S
for Cyclo Therapeutics Inc.

Provide P/E
for Cyclo Therapeutics Inc.

Provide P/OCF
for Cyclo Therapeutics Inc.

Provide P/FCFE
for Cyclo Therapeutics Inc.

Provide P/B
for Cyclo Therapeutics Inc.

Provide EV/S
for Cyclo Therapeutics Inc.

Provide EV/GP
for Cyclo Therapeutics Inc.

Provide EV/EBITDA
for Cyclo Therapeutics Inc.

Provide EV/EBIT
for Cyclo Therapeutics Inc.

Provide EV/OCF
for Cyclo Therapeutics Inc.

Provide EV/FCFF
for Cyclo Therapeutics Inc.

Provide EV/IC
for Cyclo Therapeutics Inc.

Show me price targets
for Cyclo Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Cyclo Therapeutics Inc?

How accurate were the past Revenue estimates
for Cyclo Therapeutics Inc?

What are the Net Income projections
for Cyclo Therapeutics Inc?

How accurate were the past Net Income estimates
for Cyclo Therapeutics Inc?

What are the EPS projections
for Cyclo Therapeutics Inc?

How accurate were the past EPS estimates
for Cyclo Therapeutics Inc?

What are the EBIT projections
for Cyclo Therapeutics Inc?

How accurate were the past EBIT estimates
for Cyclo Therapeutics Inc?

Compare the revenue forecasts
for Cyclo Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cyclo Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cyclo Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cyclo Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Cyclo Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cyclo Therapeutics Inc with its peers.

Analyze the financial leverage
of Cyclo Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Cyclo Therapeutics Inc.

Provide ROE
for Cyclo Therapeutics Inc.

Provide ROA
for Cyclo Therapeutics Inc.

Provide ROIC
for Cyclo Therapeutics Inc.

Provide ROCE
for Cyclo Therapeutics Inc.

Provide Gross Margin
for Cyclo Therapeutics Inc.

Provide Operating Margin
for Cyclo Therapeutics Inc.

Provide Net Margin
for Cyclo Therapeutics Inc.

Provide FCF Margin
for Cyclo Therapeutics Inc.

Show all solvency ratios
for Cyclo Therapeutics Inc.

Provide D/E Ratio
for Cyclo Therapeutics Inc.

Provide D/A Ratio
for Cyclo Therapeutics Inc.

Provide Interest Coverage Ratio
for Cyclo Therapeutics Inc.

Provide Altman Z-Score Ratio
for Cyclo Therapeutics Inc.

Provide Quick Ratio
for Cyclo Therapeutics Inc.

Provide Current Ratio
for Cyclo Therapeutics Inc.

Provide Cash Ratio
for Cyclo Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Cyclo Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Cyclo Therapeutics Inc?

What is the current Free Cash Flow
of Cyclo Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cyclo Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cyclo Therapeutics Inc

Current Assets 12.3m
Cash & Short-Term Investments 9.2m
Receivables 122.4k
Other Current Assets 2.9m
Non-Current Assets 929.3k
PP&E 929.3k
Current Liabilities 8.5m
Accounts Payable 7.5m
Accrued Liabilities 1m
Non-Current Liabilities 22.5k
Other Non-Current Liabilities 22.5k
Efficiency

Earnings Waterfall
Cyclo Therapeutics Inc

Revenue
1.1m USD
Cost of Revenue
-98.5k USD
Gross Profit
978k USD
Operating Expenses
-21m USD
Operating Income
-20.1m USD
Other Expenses
-7.3k USD
Net Income
-20.1m USD

Free Cash Flow Analysis
Cyclo Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CYTH Profitability Score
Profitability Due Diligence

Cyclo Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional ROIC
ROIC is Increasing
Positive 3-Years Revenue Growth
29/100
Profitability
Score

Cyclo Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

CYTH Solvency Score
Solvency Due Diligence

Cyclo Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
38/100
Solvency
Score

Cyclo Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYTH Price Targets Summary
Cyclo Therapeutics Inc

Wall Street analysts forecast CYTH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYTH is 3.26 USD with a low forecast of 2.63 USD and a high forecast of 4.2 USD.

Lowest
Price Target
2.63 USD
86% Upside
Average
Price Target
3.26 USD
131% Upside
Highest
Price Target
4.2 USD
198% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CYTH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CYTH Price
Cyclo Therapeutics Inc

1M 1M
+14%
6M 6M
-3%
1Y 1Y
+33%
3Y 3Y
-80%
5Y 5Y
-98%
10Y 10Y
-98%
Annual Price Range
1.41
52w Low
0.93
52w High
2.3
Price Metrics
Average Annual Return -50.85%
Standard Deviation of Annual Returns 35.79%
Max Drawdown -99%
Shares Statistics
Market Capitalization 40.3m USD
Shares Outstanding 28 720 000
Percentage of Shares Shorted 0.22%

CYTH Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cyclo Therapeutics Inc Logo
Cyclo Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

40.3m USD

Dividend Yield

0%

Description

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The firm's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The firm's product lines include Trappsol and Aquaplex. The company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Contact

FLORIDA
Gainesville Florida
6714 Nw 16Th Street,, Suite B
+13864188060.0
https://www.cyclotherapeutics.com/

IPO

2004-02-27

Employees

9

Officers

CEO & Director
Mr. N. Scott Fine
Founder & Director
Mr. C. E Strattan
CFO & Secretary
Mr. Joshua M. Fine
Global Head of Regulatory Affairs & Senior VP of Business Development
Mr. Michael Eric Lisjak
COO, Chief Quality Officer & Director
Dr. Jeffrey L. Tate Ph.D.
Global Head of Patient Advocacy
Ms. Lori McKenna
Show More
Interim Chief Medical Officer
Dr. Karen Mullen FFPM
Show Less

See Also

Discover More
What is the Intrinsic Value of one CYTH stock?

The intrinsic value of one CYTH stock under the Base Case scenario is 0.56 USD.

Is CYTH stock undervalued or overvalued?

Compared to the current market price of 1.41 USD, Cyclo Therapeutics Inc is Overvalued by 60%.